3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Melanoma
76
Neoplasms
11
Brain Neoplasms
8
Skin Neoplasms
6
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioma
2
Fever
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma, Cutaneous Malignant
1
Lymphoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
trametinib
2
liposomal amphotericin B
2
dabrafenib
2
Vancomycin
1
Tazobactam
1
Piperacillin, Tazobactam Drug Combination
1
Piperacillin
1
Moxifloxacin
1
Levofloxacin
1
Ciprofloxacin
1
Cefepime
1
Caspofungin
1
Amoxicillin-Potassium Clavulanate Combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Fever
×
dabrafenib
×
Dermatologic
×
Clear all
NCT01972347
2025-12-16
Neo Combi
Melanoma Institute Australia
Phase 2
Active not recruiting
35 enrolled
NCT03551626
2025-04-29
COMBI-APlus
Novartis
Phase 3
Completed
552 enrolled
12 charts